Although the mechanisms of aberrant RAD51C and RAD51D in conferring risk to OC is unknown, our LOH analyses of tumour DNA from carriers are consistent with independent studies that have demonstrated loss of the protein function in tumour cells. The gene discussed is RAD51D; the disease is neoplasm.